Business Overview: Azenta, Inc. (NASDAQ: AZTA)

---

Executive Summary

Azenta, Inc. is a life sciences company providing sample management solutions and genomic services to biopharma, academic, and research customers globally. Headquartered in Burlington, Massachusetts, Azenta was created in 2021 when its predecessor, Brooks Automation, divested its semiconductor automation business (which retained the Brooks Automation name) and rebranded its remaining life sciences operations as Azenta, refocusing the company entirely on life sciences infrastructure.

Azenta generates roughly $600-700 million in annual revenue, built around two complementary businesses: automated cold-chain sample storage and management systems, and genomic/laboratory services (including its GENEWIZ sequencing and synthesis business), positioning it as critical infrastructure for the growing genomics and biobanking economy.

---

1. Core Business Model & How They Work

Azenta helps biopharma, academic, and biotech customers manage one of their most valuable and irreplaceable assets — biological samples (cells, tissue, DNA, and other biospecimens) — through automated storage systems and consumables, while its genomics services business provides outsourced sequencing, synthesis, and related laboratory services.

[ Sample Management: Automated Cold-Chain Storage Systems, Consumables, Repository Services ]
                          +
[ Genomic Services (GENEWIZ): Sequencing, Gene Synthesis, Sanger Sequencing ]
                          ➡️
[ Biopharma, Academic, Biotech Customers Managing Biological Samples & Research Workflows ]

Key Operational Drivers

1. Mission-Critical Sample Integrity: Biological samples used in drug discovery, biobanking, and clinical trials are often irreplaceable; Azenta's automated, temperature-controlled storage and tracking systems address a critical infrastructure need where sample loss or degradation can be catastrophic for a customer's research program.
2. Outsourced Genomics Services Scale: Through GENEWIZ (acquired years prior to the Azenta rebrand), Azenta offers sequencing and gene synthesis services at scale, allowing biopharma and academic customers to outsource routine genomic work rather than building in-house sequencing capacity.
3. Recurring Consumables & Services Revenue: A meaningful share of Azenta's revenue comes from recurring consumables, storage services, and repository/biobanking fees rather than one-time equipment sales alone.
4. Global Biorepository Network: Azenta operates biorepositories and services facilities across multiple global regions, supporting multinational biopharma customers' sample logistics and storage needs.

---

2. Business Segments

• Life Sciences Products: Automated sample management systems (freezers, sample storage/retrieval automation), consumables, and instruments used by biopharma and academic labs to manage biological samples.
• Life Sciences Services: Genomic services (sequencing, gene synthesis via GENEWIZ), biorepository/biobanking services, and other lab support services offered on an outsourced basis to research customers.

---

3. Competitive Landscape

                     LARGE DIVERSIFIED LIFE SCIENCES TOOLS COMPANIES
                                     │
        Thermo Fisher Scientific,    │
        Illumina (sequencing),        │
        Charles River Laboratories     │
                                     │
   SPECIALIZED SAMPLE MGMT/GENOMICS ─┼───────────────── BROAD DIVERSIFIED PORTFOLIO
                                     │
              Azenta (AZTA) —         │      Thermo Fisher spans instruments,
              focused sample mgmt +    │      reagents, and services across
              genomics services         │      the entire life sciences value chain

Competitors by Domain

Sample Management & Biobanking

• Key Competitors: Thermo Fisher Scientific (broad cold-chain and lab equipment portfolio), Brooks Life Sciences legacy competitors, and various specialized biorepository/biobanking service providers.
• Dynamics: Azenta is one of the more specialized, dedicated providers of automated sample management infrastructure, competing against much larger diversified life sciences tools companies that offer sample storage as one product line among many.

Genomic Services

• Key Competitors: Illumina (sequencing instruments and, increasingly, services), Eurofins Genomics, and other contract sequencing/synthesis providers.
• Dynamics: GENEWIZ competes in a competitive outsourced genomics services market where scale, turnaround time, and quality/reliability are key differentiators; Illumina's dominant position in sequencing instrumentation gives it certain structural advantages, though GENEWIZ operates as a service provider across multiple sequencing platforms.

---

4. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• Mission-critical, high-switching-cost sample storage relationships: Once a biopharma or academic customer's irreplaceable sample library is stored in Azenta's systems and repositories, switching providers carries meaningful operational and continuity risk.
• Established global biorepository infrastructure: A worldwide network of storage and services facilities represents significant accumulated capital investment.
• GENEWIZ scale in outsourced genomics services: Provides cost and turnaround-time advantages for customers seeking to outsource routine sequencing and synthesis work.
• Recurring revenue base: A meaningful portion of revenue from consumables, storage fees, and ongoing services provides more predictable cash flow than one-time equipment sales alone.

Strategic Risks & Vulnerabilities

1. Biotech funding cyclicality: Demand for genomic services and sample management is sensitive to biotech venture funding and biopharma R&D spending cycles.
   • Mitigation Strategy: Diversification across academic, government, and larger pharma customers that are somewhat less sensitive to biotech funding volatility than smaller biotech customers.
2. Competitive intensity in genomics services: Illumina and other large sequencing players could expand further into services, intensifying competition for GENEWIZ.
3. Post-divestiture standalone scale: As a smaller, more focused company since separating from the semiconductor automation business, Azenta has less scale diversification than it did previously.
4. Capital intensity of storage infrastructure: Maintaining and expanding automated cold-chain storage facilities requires ongoing capital investment.

---

5. Financial Overview & Performance Matrix

---

6. Summary Conclusion

Azenta occupies a specialized, mission-critical niche in the life sciences infrastructure value chain — helping biopharma and academic customers manage irreplaceable biological samples and outsource genomic services — creating genuine switching-cost moats around its storage and repository relationships even as it competes against much larger diversified life sciences tools companies.

The company's long-term strategic question is whether it can continue growing its genomic services business (GENEWIZ) profitably amid competitive pressure from larger sequencing players like Illumina, while navigating the cyclicality of biotech funding that affects demand for both its sample management and genomics services businesses.